UPSHER-SMITH EXPANDS KYMBEE™ (DEFLAZACORT) FAMILY OF PRODUCTS WITH LAUNCH OF ORAL SUSPENSION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
UPSHER-SMITH EXPANDS KYMBEE™ (DEFLAZACORT) FAMILY OF PRODUCTS WITH LAUNCH OF ORAL SUSPENSION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Liquid Formulation Enhances Treatment Flexibility for Patients and Caregivers and is Supported by the Company's Promise of Support® Program
MAPLE GROVE, Minn., June 23, 2026 — Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. The oral suspension offers an additional administration option for patients and caregivers.
KYMBEE™ (deflazacort) Oral Suspension | Upsher-Smith Laboratories, LLC. Not actual size.
Summary
Liquid Formulation Enhances Treatment Flexibility for Patients and Caregivers and is Supported by the Company's Promise of Support® Program MAPLE GROVE, Minn., June 23, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472....